Table 1.
Demographic and clinicopathological characteristics of patients with resected gastric adenocarcinoma used for MSK-IMPACT™ sequencing, stratified by stage-matched extremes-of-survivorship cohorts
| MSK-EGC1 (n = 10) | MSK-EGC2 (n = 10) | MSK-LAGC1 (n = 10) | MSK-LAGC2 (n = 10) | |
|---|---|---|---|---|
| Age at diagnosis (years)* | 70 | 68 | 63 | 63 |
| Sex ratio (M : F) | 6:4 | 7:3 | 7:3 | 7:3 |
| Caucasian | 9 | 7 | 7 | 9 |
| Tumour location | ||||
| GOJ/proximal third | 4 | 2 | 0 | 3 |
| Body/middle third | 4 | 3 | 7 | 5 |
| Antrum/distal third | 2 | 5 | 3 | 2 |
| Type of gastrectomy | ||||
| Distal/proximal (subtotal) | 8 | 9 | 6 | 5 |
| Total/combined with partial oesophagectomy | 2 | 1 | 4 | 5 |
| Resection margin | ||||
| Negative (R0) | 10 | 10 | 10 | 10 |
| Positive (R1–2) | 0 | 0 | 0 | 0 |
| Extent of lymphadenectomy | ||||
| D1+ | 1 | 2 | 1 | 1 |
| D2 | 9 | 8 | 9 | 9 |
| pT category | ||||
| pT1–2 | 10 | 10 | 0 | 0 |
| pT3–4 | 0 | 0 | 10 | 10 |
| pN status | ||||
| pN0 | 10 | 10 | 0 | 0 |
| pN+ | 0 | 0 | 10 | 10 |
| Laurén classification | ||||
| Intestinal | 7 | 9 | 4 | 3 |
| Diffuse | 2 | 0 | 3 | 3 |
| Mixed | 1 | 1 | 3 | 4 |
| Adjuvant therapy | ||||
| None | 10 | 10 | 4 | 2 |
| Chemotherapy alone | 0 | 0 | 2 | 1 |
| Chemoradiotherapy | 0 | 0 | 4 | 7 |
| Disease recurrence | 10 | 0 | 0 | 10 |
| Recurrence pattern | – | – | ||
| Locoregional only | 0 | 0 | ||
| Distant only | 7 | 8 | ||
| Locoregional and distant | 3 | 2 | ||
| Salvage chemotherapy at recurrence | 8 | – | – | 9 |
*
Values are median. MSK-EGC1, patients with early gastric cancer (EGC) who had gastrectomy with curative intent at Memorial Sloan Kettering Cancer Center (MSK) with disease-specific survival of less than 5 years; MSK-EGC2, as MSK-EGC1 but with no recurrence at 5 years; MSK-LAGC1, patients with locally advanced gastric cancer without recurrence at 5 years; MSK-LAGC2, patients with locally advanced gastric cancer with recurrence at 5 years; GOJ, gastro-oesophageal junction.